Matthew Evans
Family Medicine · Phoenix, AZNPI 1821431560
Payments from drug & device makers
Across 91 payments — averaging $22.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$374
- Braeburn Inc.$199
- Indivior Inc.$182
- Novo Nordisk$166
- Alkermes, Inc.$147
- Otsuka America Pharmaceutical, Inc.$141
- plus $883 from 17 others
What the payments were for
- Food & beverage$2,01796%
- Education$754%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 19 | $374 |
| Braeburn Inc. | 5 | $199 |
| Indivior Inc. | 10 | $182 |
| Novo Nordisk | 10 | $166 |
| Alkermes, Inc. | 6 | $147 |
| Otsuka America Pharmaceutical, Inc. | 6 | $141 |
| Johnson & Johnson | 4 | $137 |
| Atricure, Inc. | 1 | $129 |
| Organon | 2 | $112 |
| AstraZeneca | 5 | $108 |
| Gilead | 5 | $92 |
| Boehringer Ingelheim | 3 | $64 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $64 |
| USWM, LLC | 2 | $33 |
| Pfizer | 2 | $29 |
| Exact Sciences | 1 | $24 |
| Astellas Pharma US Inc | 1 | $17 |
| Impulse Dynamics (USA) Inc. | 1 | $16 |
| Qiagen, LLC | 1 | $14 |
| Lilly USA, LLC | 1 | $13 |
| Boston Scientific | 1 | $11 |
| Daiichi Sankyo Inc. | 1 | $11 |
| Amgen | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- EPI-SENSE GUIDED COAGULATION SYS$129
- BRIXADI$117
- NEXPLANON$108
How this compares
$2,092 in reported general payments places this provider in the 80th percentile of 2,099 family medicine providers in Arizona.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 40 | $3,933 |
| Ondansetron Hcl | 15 | $430 |
| Lisinopril | 49 | $411 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 18 | $363 |
| Duloxetine Hcl | 13 | $335 |
| Clonazepam | 25 | $266 |
| Atorvastatin Calcium | 23 | $259 |
| Omeprazole | 17 | $251 |
| Amlodipine Besylate | 37 | $222 |
| Levothyroxine Sodium | 15 | $195 |
| Potassium Chloride | 13 | $165 |
| Alprazolam | 23 | $138 |
| Metoprolol Tartrate | 17 | $79 |
| Furosemide | 11 | $65 |
| Metformin Hcl | 12 | $56 |
Paid to pharmacies, not to this prescriber.
Other family medicine in Phoenix
- Brock MerrittPhoenix$8.4M
- Douglas CunninghamPhoenix$4.9M
- Jeffrey ZacherPhoenix$2M
- Trisha TavaresPhoenix$1.6M
- David FrancykPhoenix$1.3M
- James BeachPhoenix$1.2M
- Peter LevinsPhoenix$971K
- Elysa ShawPhoenix$774K
- Mitchell EdelsteinPhoenix$741K
- Brian DedinskyPhoenix$589K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.